Prof. Dr. rer.-nat. Alexander Steinkasserer, Dept.

CRC 1607 | Prof. Dr. rer.-nat. Alexander Steinkasserer, Dept.

Department of Immune Modulation
Universitätsklinikum Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Hartmannstr. 14
91052 Erlangen, Germany
+49 9131 – 8536728
alexander.steinkasserer@uk-erlangen.de

Projects:

Project leader

B03

Scientific career

Since 2016 Elected member of the Management Board of the “ELAN-Fonds“ for Research, Medical Faculty (FAU)

Since 2015 Elected member of the Medical Faculty Board at the FAU

Since 2015 Elected member of the Executive Board of the CRC 1181 “Checkpoints for resolution of inflammation”, funded by the DFG

2013 Organiser of the “Workshop – Systems Immunology”, Erlangen

2013 Organiser of the ”27th Annual conference – European Macrophage & Dendritic cell Society”, Erlangen

Since 2010 Mentor of the “Ariadne Mentoring Program“, for Young Female Scientists – FAU

2007 – 2016 Elected member of the Management Board of the “Interdisciplinary Center for Clinical Research“ (IZKF), Medical Faculty at the FAU

2007 Organiser of the “5th International Meeting on DC Vaccination Trials“, Bamberg

2007 Organiser of the “3rd Symposium on Strategies for Immune Intervention” Bamberg

2005 – 2014 Elected treasurer of the “European Macrophage and Dendritic Cell Society”

2004 – 2016 Elected Vice-spokesman of the CRC 643: „Strategies of cellular Immune Intervention“, funded by the DFG

2004 – 2014 Elected council member of the “European Macrophage and DC Society

2003 Organiser of the „Third International Symposium: Viruses and Immune Defence“, Erlangen

2002 Organiser of the “7th International Symposium on Dendritic Cells”, Bamberg

Since 07.1998 Professor (C3) and Head of Dept. of Immune Modulation at the University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg

08.1996-06.1998 Division-Head, Baxter AG, Vienna

11.1993 – 07.1996 Lab-Head at the Novartis Research Institute, Vienna

10.1989 – 10.1993 Research Fellow, University of Oxford

02.1986 – 09.1989 Postdoc, LM-University Munich

08.1984 –01.1986 University Assistant, University of Innsbruck

Prizes and honors

2006 Research prize winner of the „Paul-Langerhans Prize“

2003 Research prize winner of the “Berliner Stiftung für Dermatologie”

1991 First prize winner of the South Tyrolian “Futura Stiftung”

1987-1989 Postdoctoral Fellowship of the “Boehringer Ingelheim Fonds

1981-1983 Scholarship for “Highly Talented Students”, Province of South Tyrol

Selected publications

  1. Peckert-Maier K, Schönberg A, Wild AB, Royzman D, Braun G, Stich L, Hadrian K, Tripal P, Cursiefen C, Steinkasserer A, Zinser E, Bock F. (2022). Pre-incubation of corneal donor tissue with sCD83 improves graft survival via the induction of alternatively activated macrophages and tolerogenic dendritic cells. Am J Transplant.;22(2):438-454.
  2. Royzman D, Peckert-Maier K, Stich L, König C, Wild AB, Tauchi M, Ostalecki C, Kiesewetter F, Seyferth S, Lee G, Eming SA, Fuchs M, Kunz M, Stürmer EK, Peters EMJ, Berking C, Zinser E, Steinkasserer A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Front Immunol. 2022 Sep 30;13:1012647. doi:10.3389/fimmu. 2022.1012647. eCollection 2022.
  3. Royzman D, Andreev D, Stich L, Peckert-Maier K, Wild A.B, Zinser E, Mühl-Zürbes P, Jones E, Adam S, Frey S, Fuchs M, Kunz M, Bäuerle T, Nagel L, Schett G, Bozec A, and Steinkasserer A (2022). The soluble CD83 protein prevents bone destruction by inhibiting the formation of osteoclasts and inducing resolution of inflammation. Frontiers Immunol, 2022. https://doi.org/ 10.3389/fimmu.2022.936995
  4. Clahsen T, Hadrian K, […], Howaldt A […], Steinkasserer A , […], Bock, F, Cursiefen C. (2022), The novel role of lymphatic vessels in the pathogenesis of ocular diseases, Prog Retin Eye Res (accepted).
  5. Bénard A, Jacobsen A, Brunner M, Krautz C, Klösch B, Swierzy I, Naschberger E, Podolska MJ, Kouhestani D, David P, Birkholz T, Castellanos I, Trufa D, Sirbu H, Vetter M, Kremer A, Hildner K, Hecker A, Edinger F, Tenbusch M, Muehl-Zuerbes P, Steinkasserer A, et.al (2021). Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections. Nature Comm. 18;12(1):1112.
  6. Wild AB, Krzyzak L, Peckert K, Stich L, Kuhnt C, Butterhof A, Seitz C, Mattner J, Grüner N, Gänsbauer M, Purtak M, Soulat D, Winkler TH, Nitschke L, Zinser E, Steinkasserer A. (2019). CD83 orchestrates immunity toward self and non-self in dendritic cells. JCI Insight. 2019 Oct 17;4(20). pii: 126246. doi: 10.1172/jci.insight.126246.
  7. Turan A, Grosche L, Krawczyk A, Mühl-Zürbes P, Draßner C, Düthorn A, Kummer M, Hasenberg M, Voortmann S, Jastrow H, Dörrie J, Schaft N, Kraner M, Döhner K, Sodeik B, Steinkasserer A, Heilingloh CS. (2019). Autophagic degradation of lamins facilitates the nuclear egress of Herpes Simplex Virus type-1. Journal Cell Biology, 218(2):508-523.
  8. Döbbeler M, Koenig C, Krzyzak L, Seitz C, Wild A, Ulas T, Baßler K, Kopelyanskiy D, Butterhof A, Kuhnt C, Kreiser S, Stich L, Zinser E, Knippertz I, Wirtz S, Riegel C, Hoffmann P, Edinger M, Nitschke L, Winkler T, Schultze JL, Steinkasserer A, Lechmann M. (2018). CD83 expression is essential for Treg cell differentiation and stability. JCI insight, 3(11). pii: 99712. doi: 10.1172/jci.insight.99712.
  9. Rohrscheidt J, Petroziello E, Nedjic J, Federle C, Kryzak L, Ploegh H, Ishido S, Steinkasserer A, Klein L. (2016) Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83. J. Exp. Med. 213(9):1685-1694.
  10. Bock F, Rössner S, Onderka J, Lechmann M, Pallotta MT, Fallarino F, Boon L, Nicolette C, DeBenedette MA, Tcherepanova IY, Grohmann U, Steinkasserer A, Cursiefen C, Zinser E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells and prolongs allogeneic corneal graft survival. J. of Immunology; 191:1965-1975.

Patents

  1. Steinkasserer A, Lechmann M, Zinser E. Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by the dysfunction or undesired function of a cellular immune response involving T cells. US Patent No.: US 7,169,989 B2
  2. Stein MF, Knippertz I, Winkler TH, Steinkasserer A. Mutant CD83-promotor and use thereof. EU patent No. 2702158